With respect to targeted therapy to VEGFR2 by targeting the cancer cells directly, VEGFR2 and its company STAT3 are inhibited by Apatinib and BCL-2 was consequently supressed, inducing autophagy and apoptosis eventually, implying the potential benefits when combing Apatinib and autophagy inhibitors in treatment of osteosarcoma [16]. The gene discussed is BCL2; the disease is osteosarcoma.